Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evaxion Biotech A/S ADR (NQ: EVAX )

1.060 UNCHANGED
Streaming Delayed Price Updated: 3:58 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.060
Bid (Size) 0.9690 (2)
Ask (Size) 1.120 (9)
Prev. Close 1.060
Today's Range 1.060 - 1.060
52wk Range 0.9200 - 3.520
Shares Outstanding 23,203,808
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients
From Evaxion Biotech
Via Globe NewsWire
Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients
From Evaxion Biotech
Via Globe NewsWire

Performance

YTD
-39.09%
-39.09%
1 Month
-30.27%
-30.27%
3 Month
-40.79%
-40.79%
6 Month
-55.84%
-55.84%
1 Year
-66.35%
-66.35%

More News

Read More
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
From Evaxion Biotech
Via Globe NewsWire
Evaxion Biotech Highlights Promising Data From Personalized Cancer Immunotherapy
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Evaxion Biotech, Pantherna Reveals Encouraging Data From mRNA-Based Cancer Vaccine
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Evaxion and Pantherna announce promising preclinical mRNA vaccine data
From Evaxion Biotech
Via Globe NewsWire
Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
From Evaxion Biotech
Via Globe NewsWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
From Evaxion Biotech
Via Globe NewsWire
Why Dermata Therapeutics Shares Are Trading Higher By Over 100%; Here Are 21 Stocks Moving Premarket
Via Benzinga
Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023
From Evaxion Biotech
Via Globe NewsWire
Evaxion, ExpreS2ion Ink Research Pact For Cytomegalovirus Vaccine Candidate
Via Benzinga
Evaxion and ExpreS²ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate
From Evaxion Biotech
Via Globe NewsWire
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
From Evaxion Biotech
Via Globe NewsWire
Evaxion Announces Third Quarter 2022 Financial Results and Business Update
From Evaxion Biotech
Via Globe NewsWire
Evaxion CEO comments on strategic focus
From Evaxion Biotech
Via Globe NewsWire
Evaxion welcomes Per Norlén as new CEO.
From Evaxion Biotech
Via Globe NewsWire
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
US Stocks Open Higher; Dow Surges 300 Points
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.